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Abstract In this study, we compared one hundred patients with autoimmune/inflammatory syndrome induced by adjuvants
(ASIA) due to silicone implant incompatibility syndrome diagnosed in 2014 in Maastricht, the Netherlands, with one
hundred historical patients with adjuvant breast disease diagnosed in the Baylor College of Medicine, Houston, USA,
between 1985 and 1992. Similarities and differences between these two cohorts were identified to determine whether the
spectrum of silicone-related disease changed during the last 30 years. Patients with complaints possibly due to silicone-
filled breast implants were prospectively examined in the Reinaert Clinic, Maastricht, the Netherlands between January
2014 and October 2014. All patients were evaluated for the fulfilment of ASIA criteria. Results were compared to results of
the Baylor College cohort and 18 other reviewed historical cohorts. Clinical manifestations between the Maastricht and
Baylor College cohorts were comparable. Fatigue was observed in 98 current patients and in 95 historical patients.
Arthralgia was observed in 91 versus 81 historical patients. Myalgia was observed in 54 versus 91 patients. Cognitive
impairment was observed in 78 versus 81 patients, pyrexia was observed in 64 versus 52 patients, sicca complaints in 73
versus 72 patients and severe neurological manifestations in 20 versus 32 patients. From the 54 patients who underwent
removal of their silicone breast implant, 50 % (n = 27) of the patients experienced improvement of complaints after
explantation of the implant. Also, in the 18 reviewed historical cohorts, similar clinical manifestations were described. Our
findings suggest that no major changes were present in the observed clinical manifestations between the Maastricht and
Baylor College cohorts. Also, despite changes in the principal constituents of the silicone implants during the past fifty
years, silicone remained an adjuvant that may ‘bleed’ and subsequently may be a chronic stimulus to the immune system
resulting in similar clinical manifestations as observed in the Maastricht cohort, the Baylor College cohort and 18 other
large cohorts of patients. We therefore conclude that silicone-related disease has not changed during the last 30 years.
Keywords Breast implants  Silicones  Autoimmunity  Autoinflammatory  Fibromyalgia  ASIA  Chronic fatigue
syndrome (CFS)
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The safety of silicone-containing breast implants has been
challenged since their introduction [1, 2], even though the
principal constituents of implants have changed during the
last fifty years. Well-known local complications of sili-
cone-filled implants are capsular contracture, allergic
reaction and autoimmune diseases [3–8]. In addition, there
is evidence for an increased occurrence of a rare form of
non-Hodgkin lymphoma, i.e. anaplastic large T cell lym-
phoma [9–11]. Furthermore, we recently described the
increased occurrence of a deficient humoral immune sys-
tem in patients exposed to silicone-filled breast implants
[3]. Interestingly, it is at present still controversial whether
silicone-filled breast implants increase the risk of autoim-
munity [3, 12, 13]. Nearly five decades after the first
description of a syndrome called ‘adjuvant breast disease’
[1, 2] it was recognized that patients develop a specific
disease that cannot be classified as a classic connective
tissue disease (CTD) and it was proposed to label these
patients as suffering from ‘autoimmune/inflammatory
syndrome induced by adjuvants’ (ASIA) due to ‘Silicone
Implant Incompatibility Syndrome’ (SIIS) [3, 14]. Whether
ASIA due to SIIS [3, 15] is actually the same disease as the
previously described adjuvant breast disease is at present
still uncertain [2, 16]. To study this, we compared 100
consecutively diagnosed patients with ASIA due to SIIS
with 100 historical patients described as suffering from
‘adjuvant breast disease’.
Materials and methods
Two groups of patients with complaints due to silicone-
containing breast implants are compared. A cohort of one
hundred patients analysed for silicone breast implant-re-
lated complaints in 2014 in the Netherlands (‘Maastricht
cohort’) and a cohort of one hundred patients diagnosed at
Baylor College, Houston, Texas, USA, with ‘Adjuvant
Breast disease’ due to silicone breast implants or silicone
fluid injections between 1985 and 1992 as described in
1994 by Shoaib et al. (‘Baylor College cohort’) [16].
Matching criteria between the two cohorts are Shoen-
feld’s criteria for the diagnosis of ASIA (Table 1). Patients
who developed complaints after receiving silicone breast
implants were referred to and evaluated by JWCT between
January 2014 and October 2014 for prospective analysis
(‘Maastricht cohort’). All patients received a careful eval-
uation of their complaints, their medical history and a
physical examination [3, 17]. A diagnosis of ASIA was
made when Shoenfeld’s criteria for this syndrome were
fulfilled [14]. Explicit four major and four minor criteria
were evaluated; the patient was considered having ASIA
when either two major or one major and two minor criteria
were present (Table 1). The first consecutive hundred
patients who fulfilled Shoenfeld’s criteria for the diagnosis
of ASIA were included in this study. Patients underwent
laboratory measurements of immunoglobulins, antinuclear
antibodies (ANA) and IgM rheumatoid factor (RF) [3, 18].
In addition, extractable nuclear antigen (ENA), antineu-
trophil cytoplasmic antibodies (ANCA), anticyclic citrul-
linated peptide (anti-CCP) were measured and several
other autoantibodies (e.g. anticardiolipin antibodies) were
measured in patients clinically suspected of suffering from
specific autoimmune diseases [3]. Immunoglobulins IgG,
IgA and IgM were tested by latex-enhanced homogenous
immunoassay by antigen–antibody complex with spec-
trophotometry by Turbidimetry, Roche Cobas, Roche,
Basel, Switzerland. Antinuclear antibodies were tested by
indirect immunofluorescence on HEp-2000 cells (Immuno
Concepts, Sacramento, CA) [17]. Serum samples were
screened in a dilution of 1:80 [19]. IgM rheumatoid factor
was tested by FEIA (Phadia ImmunoCAP 250, Ther-
moFisher Scientific, Freiburg, Germany) [20]. If explan-
tation of silicone implants was performed, patients were
reassessed by JWCT to document whether changes of
complaints had occurred after explantation. Also, this
assessment focussed on the different clinical manifesta-
tions of Shoenfeld’s ASIA criteria. The comparative group
of patients, described by Shoaib et al. [16] in 1994 was
composed of 100 symptomatic women with human adju-
vant breast disease due to silicone incompatibility. These
Table 1 Criteria for the diagnosis of ASIA
Major criteria
• Exposure to an external stimulus (infection, vaccine, silicone,
adjuvant) prior to clinical manifestations
• The appearance of ‘typical’ clinical manifestations:
- Myalgia, Myositis or muscle weakness
- Arthralgia and/or arthritis
- Chronic fatigue, un-refreshing sleep or sleep disturbances
- Neurological manifestations (especially associated with
demyelination)
- Cognitive impairment, memory loss
- Pyrexia, dry mouth
• Removal of inciting agent induces improvement
• Typical biopsy of involved organs
Minor criteria
• The appearance of autoantibodies or antibodies directed at the
suspected adjuvant
• Other clinical manifestations (i.e. irritable bowel syndrome)
• Specific HLA (i.e. HLA DRB1, HLA DQB1)
• Evolvement of an autoimmune disease (i.e. multiple sclerosis,
systemic sclerosis)
ASIA autoimmune/inflammatory syndrome induced by adjuvants
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patients were evaluated for their symptoms primarily by an
outside plastic surgeon and secondly by a neurologist in the
Baylor College of Medicine (‘Baylor College Cohort’).
Statistics
For statistical analysis of results, a two-group Chi-square
test with a 0.05 two-sided significance level was used
(SPSS 22.0 software, IBM Corp, Armonk, NY).
Review
We performed a literature search in PubMed, MEDLINE,
EMBASE and the Cochrane Database of Systematic
Reviews in February 2016. Additional citations were soli-
cited from references in selected articles. The searches
combined the following main terms: silicone breast
implant, silicone adverse effects and the terms silicone-
related symptom complex, adjuvant breast disease, human
adjuvant disease, ASIA syndrome were separately added to
the main two search terms.
We included articles focussing on patients with breast
implants who were experiencing complaints that were
ascribed to their silicone breast implants. Articles focussing
on well-defined diseases, such as autoimmune or connec-
tive tissue diseases, were excluded. Articles in the period
from January 1960 to the present time, in English were
included. For all the included studies, the clinical mani-
festations in patients with silicone-related complaints were
collected. Only case series (minimal 30 patients) were
included, and no case reports were included. Studies
focussing on malignancies in the breast (diagnostics,
therapy or reconstruction) and implant failure (rupture,
infection, capsular formation) were excluded.
Results
Patient demographics
The Maastricht cohort consists of 99 female patients and 1
transgender. All patients are exposed to silicone gel-filled
breast implants. The median age at time of implantation
was 33 years (14–56 years), and the median age at onset of
clinical symptoms was 41 years (20–68 years). The med-
ian latency period from time of implant until onset of
clinical symptoms was 4 years (range 1–39 years). The
median age at the time of diagnosis was 49 years
(27–72 years). The median time between implant and
diagnosis was 13 years (2–43). The comparative group of
patients, the Baylor College cohort described in 1994,
existed of 100 symptomatic women with either silicone
breast implants (n = 97) or silicone fluid injections
(n = 3). Median age was comparable to the median age of
the patients from the Maastricht cohort (Table 2).
In both cohorts, patients received various sorts of
implants from different manufacturers. All implants,
however, were silicone gel-filled breast implants.
In both cohorts, approximately 70–80 % of the patients
received silicone breast implants for cosmetic reasons.
Other reasons for implantation were reconstruction after
benign or malignant tumour removal, or reconstruction
after preventive ablation due to a BRCA mutation
(Table 2).
Table 2 Patient demographics of both the cohorts including reasons for implantation
Variable 1994 2014
Years (range) Years (range)
Median age at time of evaluation NA 49 (27–72)
Median age at time of implantation 32 (19–52) 33 (14–56)
Median age at onset of symptoms 38 (23–57) 41 (20–68)
Median age at time of diagnoses NA 49 (27–72)
Median latency period 6 (0–24) 4 (1–39)
Median time between implant and diagnosis NA 13 (2–43)
Median age at time of removal 44 (30–59) 49 (31–68)
Reasons for implantation 1994 2014
N (%) N (%)
Cosmetic purposes 68 80
Malignant tumour 4 14
Benign tumour 28 3




Local manifestations and complications
In the Maastricht cohort, local problems were frequently
observed: capsular contracture (n = 29), sweating and/or
leakage of the silicone implant (n = 13), implant rupture
(n = 25), dislocation of the implant (n = 3) or local ten-
derness (n = 4). Furthermore, 70 patients had painful
lymphadenopathy involving the axillary regions, often with
cervical and/or inguinal lymphadenopathy as well.
In the Baylor College cohort of 1994, 76 patients suf-
fered from local problems defined as capsular contracture,
tenderness, soreness or pain of the breasts, burning and
swollen breasts, infections, numbness of the nipples or
discharge from the nipples. Fifty-eight patients had
lymphadenopathy.
Clinical symptoms
In the Maastricht cohort, arthralgia (n = 91) and chronic
fatigue (n = 98) are most often observed, followed closely
by the other typical clinical manifestations of ASIA
(Table 3). Other manifestations that were scored in the
Maastricht cohort are Raynaud’s phenomenon, irrita-
ble bowel syndrome (IBS), recurrent respiratory tract
infections, recurrent cystitis, livedo reticularis and allergies
(Table 4). In the Baylor College cohort, comparable
numbers of clinical manifestations have been identified
(Tables 3, 4).
Laboratory findings
In the Maastricht cohort, fewer patients had antinuclear
antibodies when compared to the cohort as described in
1994 (Table 5). In eight patients laboratory measurements
for IgM rheumatoid factor could not be performed, and in
two patients laboratory measurements for immunoglobu-
lins could not be performed, due to an inadequate volume
of serum. Herefore this data is reported as missing data.
Presence of autoimmune diseases
In the Maastricht cohort, 34 patients were diagnosed with
an autoimmune disease (Table 6). The presence of
autoimmune diseases has not been described in the Baylor
College cohort.
Implant removal
In the Maastricht cohort, 54 patients underwent removal of
their silicone breast implant. Of these, 50 % (n = 27) of
the patients experienced improvement of complaints after
Table 3 Presence of clinical manifestations in both cohorts
Symptom 1994 2014 P value
N (%) N (%)
Myalgia, Myositis or muscle weakness 91 54 \.001
Arthralgia and/or arthritis 81 91 .04






Cognitive impairment, memory loss 81 78 .60
Pyrexia 52 64 .09
Dry eyes and/or dry mouth (sicca) 72 73 .87
Table 4 Presence of other clinical manifestations in both cohorts
Symptom 1994 2014 P value
N (%) N (%)
Raynaud’s phenomenon 58 30 \.001
Irritable bowel syndrome NA 17 –
Recurrent respiratory tract infections NA 54 –
Recurrent cystitis NA 36 –
Livedo reticularis 62 28 \.001
Allergies 52 52 NS
NA not applicable
Table 5 Laboratory findings
Measurement 1994 2014
N (%) N (%)
Increased immunoglobulins 13/76 (17) 14/98 (14)
Decreased immunoglobulins 24/76 (32) 13/98 (13)
ANA 33/93 (36) 5/100 (5)
RF 10/90 (11) 4/92 (4)
Immunoglobulins include total IgG, IgA and IgM, ANA antinuclear
antibodies, RF IgM rheumatoid factor
Table 6 Diagnostic findings in 100 patients with silicone-filled







RA rheumatoid arthritis, CTD connective tissue disease (systemic
sclerosis n = 2, undifferentiated connective tissue disease n = 1,
Sjogren’s syndrome n = 5, antiphospholipid syndrome n = 7, sys-
temic lupus erythematosus n = 3); granulomatous disease (Crohn
n = 1, sarcoidosis n = 2); Other autoimmune diseases (multiple
sclerosis n = 1, M. Hashimoto n = 2, polychondritis recidivans
n = 1, pernicious anaemia n = 1, lichen planus n = 1 and neuralgic
amyotrophy n = 1)
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explantation of the implant. The median age at removal
was 49 years (range 31–68). Symptoms such as fatigue,
arthralgia, myalgia, sicca and pyrexia improved in most
patients after explantation. In seven patients, however, the
improvement was only observed temporarily, with a
relapse of complaints after several weeks follow-up.
In the Baylor College cohort, 96 patients underwent
explantation of the implant. The median age of the patients
at explantation was 44 years (range 30–59). Whether these
patients experienced improvement of their complaints after
explantation was not described in the paper.
Statistics
We found significant differences between the two cohorts
for the following clinical manifestations: myalgia, myositis
or muscle weakness (p\ .001) and arthralgia and/or
arthritis (p = .04). Other clinical manifestations were not
found to be significantly different: chronic fatigue
(p = .25), neurological manifestations (p = .05), cognitive
impairment (p = .60), pyrexia (p = .09) and sicca
(p = .87). Significant differences, however, were also
observed between the two cohorts regarding livedo retic-
ularis (p\ .001) and the occurrence of Raynaud’s phe-
nomenon (p\ .001) but not in the occurrence of allergies.
Discussion
The objective of this study was to explore whether ASIA
due to SIIS is the same disease as the previously described
adjuvant breast disease [16]. The results in this study show
that clinical findings in patients with silicone breast
implants in the current Maastricht cohort and the historical
Baylor College cohort are more or less identical (Table 3).
The typical clinical manifestations (major criterion 2 of the
ASIA syndrome, Table 1) are clearly present in both
cohorts. In the Maastricht cohort, almost all patients pre-
sented with fatigue, in combination with arthralgia and/or
myalgia. These symptoms were nearly always accompa-
nied with pyrexia, cognitive impairment and/or sicca
complaints.
There are, however, differences between both cohorts.
Myalgia was less frequently observed in the Maastricht
cohort in comparison with the Baylor College cohort,
whereas arthralgia/arthritis was more frequently observed
in the Maastricht cohort. The difference could be due to the
fact that arthralgia and myalgia are difficult to distinguish.
Both symptoms have a musculoskeletal origin; the true
origin of the pain is therefore sometimes difficult to
establish. Another explanation might be that Shoaib et al.
[16] (a neurologist) did a more complete neurological
work-up, whereas the auto-immunologist in Maastricht
performed a more complete rheumatological work-up [3].
Shoaib et al. have performed MRI’s, muscle biopsies,
electromyograms and specific measurements of autoanti-
bodies (anti-GM1) to detect neurological diseases. These
factors possibly explain why myalgia/myositis/muscular
weakness and neurological manifestations scored higher in
the Baylor College cohort.
Comparing the frequency of positive antinuclear anti-
bodies and IgM rheumatoid factor between the two cohorts,
less autoantibodies were detected in the Maastricht cohort
compared to the Baylor College cohort. It could be that
current silicone breast implants are less immunogenic,
explaining fewer autoantibodies in the Maastricht cohort.
Otherwise, the definitions of a positive ANA and/or posi-
tive rheumatoid factor may have been different. Unfortu-
nately, from the Baylor College cohort, the exact
description of ANA and rheumatoid factor measurement
and interpretation is lacking and detailed information about
cut-off values for ANA and IgM-RF are not described in
the paper by Shoaib [16].
In another study, in 156 women with adjuvant breast
disease performed at the University of Missouri-Columbia
in 1993, a positive ANA was found in 22 % of the patients
and a positive IgM-RF in 9 % of patients [21]. These
results resemble more closely the results of autoantibody
testing in the Maastricht cohort, suggesting that anti-
genicity of the breast implants did not change during the
last 30 years. Finally, in the Maastricht cohort, the course
of disease has been evaluated after explantation of the
silicone breast implant. Improvement of complaints
occurred in 50 % of the patients. In another study, con-
ducted by Peters et al. in 1997, a similar outcome was
reported: 58 % of their patients had fewer symptoms after
explantation, whereas 74 % of the patients declared that
they ‘felt better’ and that their quality of life had improved
[22].
Review of current literature
Based on the similarities between the Maastricht and the
Baylor College cohort, we decided to conduct a critical
review of the literature, to study whether these similarities
were also present in patients who have presented with
silicone-related complaints in other studies. The results are
presented in Table 7.
Our literature search yielded 390 citations. In total, 18
studies were included; 5 studies met eligibility criteria and
were included. Thirteen studies were references in the
previous included studies, met eligibility criteria and were
included as well.
Maijers et al. [15] presented a cohort of 80 patients with
silicone breast implants and unexplained symptoms such as
fatigue, neurasthenia, myalgia, arthralgia, morning stiffness
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and night sweats in more than 60 % of women. In addition,
women experienced cognitive problems, dermatological
symptoms, gastrointestinal symptoms, alopecia, sleeping
disorders and depression.
Cohen Tervaert et al. [3] presented a cohort of 32
patients with silicone breast implants. Patients presented
with fatigue, arthralgia, myalgias, asthenia and/or fever. In
addition, 50 % of patients had an immunodeficiency,
whereas also 50 % had an autoimmune disease.
Contant et al. [23] prospectively evaluated a cohort of
57 women with silicone-related symptom complex that
were seen in an breast cancer centre between March 1995
and March 1997, who presented with sicca symptoms (dry
eyes and dry mouth), arthralgias/arthritis, Raynaud’s
Table 7 Summary of identified clinical manifestations in reviewed cohorts
References Cohort
(N)








80 X X X NR NR NR X Dermatological problems, alopecia,





32 X X X NR X NR NR Asthenie
Contant
[23]




63 NR X NR X NR X X Raynaud, headache, palpitations,
diarrhoea, transpiration, night
sweats, rashes
Shoaib [25] 26 NR X X X X X NR Headache, skin rash, Raynaud’s, hair




300 X X NR X X X X Headache, night sweats, diarrhoea,
recurrent infections, dyspnoea,
angio-oedema and shoulder pain
Gaubitz
[27]
90 X X X X NR NR NR Night sweats, Raynaud, tingling,
photosensitivity, headache,
dyspnoea, depression, hoarseness
Giltay [28] 235 NR X NR NR NR NR NR Skin abnormalities, burning eyes
De Jong
[29]
42 X X X X X NR NR Rashes, oral ulcers
Englert
[30]
458 NR NR X NR NR NR X Night sweats, breast pain, reflux,
paraesthesiae, lethargy
Vasey [31] 50 X X X NR NR NR NR Lymphadenopathy
Vermeulen
[32]








50 X X NR X NR NR NR Raynaud, alopecia, lymphadenopathy,
night sweats, sore throats
Solomon
[35]
176 X X NR X NR NR X Skin abnormalities, gland
enlargement, dysphagia, carpel
tunnel syndrome, alopecia




240 X X NR NR X X X Dysphagia, hair loss, depression, skin
rash, headache
Wells [37] 52 X X X NR X NR X Headaches, swollen glands, back
pain, rashes
X present symptom, NR not reported
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phenomenon, headache, dizziness, memory difficulties,
palpitations, diarrhoea and transpiration.
In another study, Contant et al. evaluated the serology of
63 women with silicone-related symptom complex who
presented with complaints as described in the above men-
tioned study of Contant. These patients were examined
between September 1990 and May 1995 [24]. They found
that 16 % of the patients were ANA positive, but there was
no difference in symptoms between ANA-positive and
ANA-negative patients.
Shoaib et al. presented 26 women with a systemic dis-
ease with central nervous system involvement after
receiving silicone breast implants or silicone fluid injec-
tion, with symptoms suggesting a multiple sclerosis-like
syndrome. Additional symptoms were myalgia, joint stiff-
ness, arthralgia, sicca complex, headache, skin rash, joint
swelling, Raynaud’s phenomena, fever, hair loss, allergies,
sensitivity to sunlight and lymphadenopathy [25].
Cuellar et al. evaluated a cohort of 300 consecutive
women seen in the Rheumatology department of the LSU
Medical Center at New Orleans from January 1991 to
November 1992 with silicone breast implants with mus-
culoskeletal complaints: chronic fatigue, arthralgia, low-
grade fever, sicca, memory loss, multiple sclerosis-like
syndrome, night sweats, headaches, chronic diarrhoea,
recurrent infections, dyspnoea and angio-oedema [26].
Gaubitz et al. [27] presented 90 consecutive symp-
tomatic women with silicone breast implants who under-
went an MRI to detect implant rupture. These patients
presented with a scala of symptoms: fatigue, arthralgia,
myalgia, night sweats, dry eyes, swollen joints, Raynaud,
tingling, photosensitivity, headache, dyspnoea, depression
and hoarseness. Clinical symptoms in patients with rup-
tured SBI did not differ from patients with an intact SBI.
Giltay et al. presented a study in which 235 patients with
silicone breast implants and 210 healthy controls filled in a
questionnaire reflecting complaints such as painful or
swollen joints, burning eyes, oral ulcers, Raynaud’s phe-
nomenon and/or skin abnormalities. Patients with silicone
breast implant significantly reported more complaints after
surgery than before surgery. Especially, more painful
joints, burning eyes and skin abnormalities were reported
compared to the control group [28].
De Jong et al. present a cohort of 42 symptomatic
patients with silicone breast implants who were evaluated
for antipolymer antibodies. These patients presented with
symptoms as fatigue, arthralgia, morning stiffness, myal-
gia, sleep disturbance, rashes, dry eyes/mouth, oral ulcers,
muscle weakness and fevers [29]. SBI exposure did not
result in induction of polymer binding antibodies.
Englert et al. evaluated 458 female patients with silicone
breast implants compared to a control group of 687 women
who underwent plastic surgery but did not receive silicone
breast implants. They found that patients with silicone breast
implants more commonly had complaints such as night
sweats, lethargy, breast pain, impaired mentation, reflux,
paraesthesiae, hand muscle weakness and myalgia [30].
Vasey et al. presented the clinical findings in a cohort of
50 symptomatic patients with silicone breast implants. The
most common clinical findings included chronic fatigue,
muscle pain, joint pain, joint swelling and lym-
phadenopathy [31].
Vermeulen et al. studied the presence of symptoms of pain
and fatigue in a cohort of 319 women with silicone breast
implants. The four most frequent complaints in the women
with implants weremulti-joint pain,muscle pain, debilitating
chronic fatigue and postexertional malaise. Fewer women
had un-refreshing sleep, impaired cognition and headache,
whereas one-third or fewer of the women with implants
complained of painful lymph nodes and sore throat [32].
Bridges et al. clinically and immunologically evaluated
156 women with silicone breast implants and symptoms of
a rheumatic disease. These patients presented with fatigue,
myalgia, arthralgia, sicca symptoms, mental confusion,
pulmonary symptoms, alopecia, recurrent fever, lym-
phadenopathy and mucosal ulcerations [33].
Freundlich et al. described typical sicca complaints in
combination with a pattern of rheumatic symptoms (fa-
tigue, generalized stiffness, poor sleep and arthralgias) in
50 female patients with silicone gel breast implants. They
concluded that their patients did not fit into one single
autoimmune, rheumatologic or neurological disease. Other
problems in these patients included Raynaud’s phe-
nomenon, alopecia, lymphadenopathy, night sweats and
frequent sore throats [34].
Solomon et al. presented a clinical and laboratory profile
of 176 symptomatic women with silicone breast implants.
The most frequent symptoms seen in the women were
chronic fatigue, cognitive dysfunction, arthralgia, dry
mouth, dry eye, alopecia, dysphagia, telangiectasias, ery-
thema of the chest wall, carpal tunnel syndrome, petechiae,
lacrimal gland enlargement, thyroid tenderness, thyroid
enlargement and parotid enlargement [35].
Peters et al. reported 100 female patients who underwent
explantation of their breast implants. Patients had systemic
symptoms such as arthralgia, myalgia, fatigue, gastroin-
testinal symptoms, rashes, memory loss, sleep disturbances
and breast pain [22].
Mehmed et al. presented 240 patients undergoing
explantation of their silicone breast implants. 196 patients
underwent explantation with complaints such as chronic
fatigue, memory loss, arthralgias, dysphagia, depression,
altered sleep patterns, hair loss, skin rashes, headaches, flu-
like symptoms and atypical multiple sclerosis [36].
Finally, Wells et al. presented 52 women requesting
removal of their silicone breast implants because they
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suspected a relation with complaints such as arthralgia,
fatigue, myalgia, headaches, fevers, swollen glands, back
pain, rashes, memory loss and swollen joints [37].
Summary of the reviewed literature
A summary of the clinical manifestations identified in the
cohorts is given in Table 7. The clinical manifestations of
ASIA major criterion 2 are used as guideline (see Table 1);
other symptoms are summarized under the heading ‘other’.
After comparing the Maastricht cohort and the Baylor
College cohort with the other identified studies, we con-
cluded that a great similarity in clinical manifestations
exists in all studies. Especially, the 7 typical clinical
manifestations of ASIA (major criterion 2) are present
throughout all identified cohorts. However, it should be
noted that several other symptoms are frequently present,
such as Raynaud’s phenomenon, headache, alopecia or hair
loss, skin abnormalities, gastrointestinal symptoms (irrita-
ble bowel syndrome), night sweats and lymphadenopathy.
These clinical findings in patients with silicone breast
implants resemble the clinical picture of fibromyalgia
[38–40]. It has been postulated that in fibromyalgia, noci-
ceptive signals (often psychological traumas) cause the
development of symptoms via disturbed pain processing
[41]. We propose that in patients with ASIA due to SIIS,
the breast implant might be the nociceptive stimulus. The
nociceptive stimulus (silicone) in combination with
extensive worrying about the safety of the breast implant
causes a disturbed pain signalling pathway and excessive
stimulation of neurotransmitters in the central nervous
system and subsequently the systemic complaints [41]. A
major difference between idiopathic fibromyalgia and sil-
icone-induced fibromyalgia, however, is the co-occurrence
of immune deficiency [3] and/or autoimmunity [3, 15, 42]
during follow-up in patients with ASIA due to SIIS.
Conclusion
Are silicone breast implants safe? After half a century of
worldwide usage, this is still a matter of debate. In 1992, the
FDA restricted the use of silicone breast implant in the USA
due to reports of fibromyalgia-like health complaints, sys-
temic symptoms and autoimmunity [43]. In 2000, Janowsky
et al. [12] performed a meta-analysis and concluded that
silicone breast implants could be considered safe. However,
in thismeta-analysis a study of 10.830 patientswas excluded,
due to the fact that the complaints of these patientswere ‘self-
reported’ [44]. If this studywas not excluded, the relative risk
for developing connective tissue disease would have
increased from insignificant to significant with a value of 1.3
[44]. Furthermore, in the meta-analysis by Janowsky et al.
[12] only the development of well-defined connective tissue
disease was addressed, and not the development of ASIA,
adjuvant breast disease or other less well-defined conditions.
This should imply that despite changes in the principal
constituents of the silicone implants during the past fifty
years, silicone remained an adjuvant that may ‘bleed’ and
subsequently may be a chronic stimulus to the immune
system resulting in similar clinical manifestations as
observed in theMaastricht cohort, the Baylor College cohort
and 18 other large cohorts of patients.
In conclusion, we report that there is a group of patients
who develop complaints related to silicone breast implants.
In the past thirty years, the character of silicone-related
complaints has been similar. Whether silicone breast
implants are safe, or if they are only safe in a subgroup of
female patients, is however, after more than these thirty
years, still not clear. This should be studied in future epi-
demiological and experimental studies. This research
should be conducted, because the current evidence that
silicone breast implants are safe is at present limited.
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